Dermal and Gynecological Acceptability (Irritability and Sensitization in the Genital Mucosa) of an Investigational Product and Evaluation of Moisture Efficacy by TEWL and Perceived Efficacy.

NCT ID: NCT03007615

Last Updated: 2017-01-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety of an investigational product through the verification of signs of irritability and sensitization of the genital mucosa, as well as the instrumental moisturizing efficacy by TEWL and barrier integrity analysis, in addition to the efficacy perceived by the volunteers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Female Dry Genital Mucosa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

Group Type EXPERIMENTAL

Intimate Lubricant Gel

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intimate Lubricant Gel

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy female sex with active sex life;
* Age group: between 45 and 65 years old;
* Menopause for at least six months;
* Whole skin in the region of product analysis;
* No history of reaction to products of the same category
* Understanding, agreement and signature of the Term of Free and Informed Consent.

Exclusion Criteria

* Gestation or risk of gestation;
* Use of anti-inflammatory / immunosuppressive drugs (in the last 30 days and during the study);
* Active cutaneous pathologies (local and / or disseminated) in the evaluation area;
* Pathologies that cause suppression of immunity, such as diabetes, HIV, etc.;
* Endocrine pathologies such as thyroid disorders, ovarian or adrenal gland disorders;
* Any infection in the region of analysis of the product diagnosed at the time of inclusion;
* Other conditions considered by the investigating physician as reasonable for disqualification of the individual from the study participation.
Minimum Eligible Age

45 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kley Hertz S/A

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Kley Hertz 007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Topical Ketotifen 0.25% for Secondary Vestibulodynia
NCT07257029 NOT_YET_RECRUITING PHASE2